Business Context and Reporting Period
The filing is The Beauty Health Company’s Form 10-K for the fiscal year ended December 31, 2021. The company, formerly Vesper Healthcare Acquisition Corp., completed its business combination with HydraFacial on May 4, 2021. The transaction was accounted for as a reverse recapitalization, and the consolidated financial statements primarily represent the continuation of HydraFacial’s historical operations.
The company operates a global beauty-health business centered on the HydraFacial brand. Its model combines sales of capital equipment, or Delivery Systems, with recurring sales of Consumables. Products were available in more than 90 countries, and approximately 30% of full-year revenue came from outside the United States and Canada.
Key Financial Metrics
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Net sales | $260.1 million | $119.1 million | Up 118.4% |
| Delivery Systems sales | $139.5 million | $53.4 million | Up 161.3% |
| Consumables sales | $120.6 million | $65.7 million | Up 83.5% |
| Gross profit | $181.8 million | $67.2 million | Up 170.6% |
| GAAP gross margin | 69.9% | 56.4% | Up 13.5 percentage points |
| Loss from operations | $(36.6) million | $(17.2) million | Loss increased |
| Net loss | $(375.1) million | $(29.2) million | Loss increased materially |
| Adjusted EBITDA | $32.7 million | $7.7 million | Up 324.0% |
| Adjusted EBITDA margin | 12.6% | 6.5% | Up 6.1 percentage points |
| Adjusted net income (loss) | $4.5 million | $(12.1) million | Improved to profit |
| Cash flow from operating activities | $(28.4) million | $(12.4) million | Greater use of cash |
| Cash flow from investing activities | $(37.7) million | $(3.8) million | Higher investment |
| Cash flow from financing activities | $959.0 million | $18.3 million | Significant increase |
| Cash and cash equivalents at year-end | $901.9 million | $9.5 million | Significant increase |
GAAP net loss was substantially affected by non-cash fair-value losses of $277.3 million on warrant liabilities and $47.1 million on earn-out share liabilities. Other notable charges included $34.9 million of transaction-related costs, $12.4 million of stock-based compensation, $13.3 million of amortization, and $4.3 million of debt prepayment penalties and deferred financing write-offs.
At December 31, 2021, total assets were $1.22 billion, total liabilities were $916.5 million, and stockholders’ equity was $302.3 million. The company had $729.9 million of convertible notes, net of issuance costs, and $93.8 million of warrant liabilities.
Material Changes Versus the Prior Comparable Period
- Revenue more than doubled, reflecting recovery from COVID-19-related disruptions, higher Delivery System sales, increased Consumables utilization, and growth in international markets.
- Gross margin expanded from 56.4% to 69.9%, primarily from fixed-cost leverage, cost-saving initiatives, product mix, and margin contribution from distributor acquisitions, partly offset by higher logistics costs.
- Operating expenses increased to $218.5 million from $84.4 million. Selling and marketing expense rose to $111.6 million, research and development to $8.2 million, and general and administrative expense to $98.7 million.
- General and administrative expense included approximately $33.0 million of increased transaction-related costs, including $21.0 million paid to the former owner of HydraFacial, as well as higher public-company, personnel, and stock-based compensation costs.
- Operating cash flow remained negative despite positive Adjusted EBITDA, principally because of the net loss and a $31.0 million increase in accounts receivable, along with higher inventory and other operating assets.
- The company acquired distributors in Australia, France, Germany, and Mexico for approximately $22.9 million of net cash consideration and issued approximately 590,000 shares as acquisition consideration.
- The company directly entered new international markets through the distributor acquisitions and reported that 35% of fourth-quarter 2021 revenue came from outside the United States and Canada.
Debt, Liquidity, Guidance, and Outlook
In September 2021, the company issued $750.0 million of 1.25% Convertible Senior Notes due October 2026. Net proceeds were approximately $638.7 million after capped-call transaction costs and debt issuance costs. The initial conversion price was approximately $31.76 per share, and the notes may represent approximately 23.6 million potential shares if converted, subject to the terms of the notes.
The company also entered into a $50.0 million revolving credit facility maturing December 30, 2026. It was undrawn at year-end. The facility includes a leverage-ratio covenant of no greater than 3.00 to 1.00 and a fixed-charge coverage ratio of at least 1.15 to 1.00. Management stated that the company was in compliance with its debt covenants and believed available liquidity was sufficient for at least the next twelve months.
The company expected capital expenditures of up to $20.0 million in 2022. Management expects continued investment in sales, marketing, research and development, technology, international expansion, and public-company infrastructure. The filing does not provide a formal quantitative revenue or earnings outlook.
Product and platform initiatives include the Syndeo next-generation Delivery System, expected to launch in the first half of 2022, and the HydraFacial Nation consumer application. Expansion of Keravive into new markets was paused because of COVID-19, and management stated that a relaunch would take time.
Management Commentary, Risks, Contingencies, and Unusual Items
- COVID-19 continued to create uncertainty through provider closures, changes in consumer behavior, supply-chain constraints, shipping delays, and potential disruptions to manufacturing and distribution.
- The company relies substantially on third-party suppliers, distributors, freight providers, and providers that generally have no obligation to purchase products or promote treatments. Certain components have single-source or limited-source suppliers.
- The beauty-health market is highly competitive and subject to rapid changes in consumer preferences, pricing, technology, product trends, and marketing channels.
- The company is subject to extensive FDA, foreign medical-device, cosmetics, product-safety, privacy, advertising, and healthcare-related regulation. Regulatory changes, product recalls, unsubstantiated claims, or loss of clearances could materially affect results.
- International operations expose the company to foreign exchange, tariffs, trade restrictions, political and economic instability, regulatory changes, and supply-chain risks, particularly in China and other growth markets.
- Management identified a continuing material weakness in internal control over financial reporting related to insufficient accounting resources. Disclosure controls and procedures were concluded to be ineffective as of December 31, 2021. The company was not required to provide management’s internal-control assessment or an auditor attestation because of the applicable transition period for newly public companies.
- The CEO transitioned from Clinton Carnell at December 31, 2021. Andrew Stanleick became CEO on February 7, 2022, following a short interim period led by Executive Chairman Brenton Saunders.
- All public warrants were exercised or redeemed during 2021; approximately 7 million private-placement warrants remained outstanding at year-end and continued to be recorded as liabilities at fair value.
- The company reported no material pending legal proceedings as of December 31, 2021. It had contractual obligations of approximately $822.2 million, including $796.9 million of notes principal and interest, $18.1 million of operating leases, and other purchase, contingent consideration, and seller obligations.
Most Important Facts for Investors to Verify
- Whether strong 2021 revenue growth and margin expansion are sustainable after the post-COVID recovery and the unusually significant increase in Delivery System sales.
- The extent to which the $375.1 million GAAP net loss reflects recurring operating economics versus non-cash warrant and earn-out fair-value losses and one-time transaction costs.
- Whether negative operating cash flow improves as revenue growth converts into Consumables utilization and recurring cash generation.
- The company’s ability to service or refinance the $750.0 million convertible notes due in 2026 and the potential dilution from conversion, warrants, equity awards, and other securities.
- Progress in remediating the material weakness in accounting resources and improving disclosure controls and financial reporting processes.
- Execution of the Syndeo launch, HydraFacial Nation app, international expansion, and integration of the four acquired distributors.
- Exposure to COVID-19 or other provider disruptions, supply shortages, freight costs, tariffs, regulatory actions, product-liability claims, cybersecurity incidents, and changing consumer demand.